9 Realms Cybersecurity
AdvisoriesCVE-2015-5287

Red Hat Automatic Bug Reporting Tool Privilege Escalation Vulnerability

Red HatAutomatic Bug Reporting ToolAdded August 26, 2026

CISA Known Exploited Vulnerabilities Data

Description

Red Hat Automatic Bug Reporting Tool (ABRT) contains a privilege escalation vulnerability that could allow local users with certain permissions to gain privileges via a symlink attack on a file with a predictable name. The impacted product(s) could be end-of-life (EoL) and/or end-of-service (EoS). Users are advised to discontinue use and/or transition to a supported version.

Required Action

Apply mitigations in accordance with vendor instructions, ensuring compliance with CISA’s BOD 26-04 Prioritizing Security Updates Based on Risk (see URL in Notes) guidance and CISA’s “Forensics Triage Requirements” (see URL in Notes). Follow applicable BOD 26-04 guidance for cloud services or discontinue use of the product if mitigations are unavailable. Stakeholders are responsible for evaluating each asset's internet exposure and ensuring adherence to BOD 26-04 patching guidelines.

CISA Due Date

September 9, 2026 (federal agency requirement)

Known Ransomware Campaign Use

Unknown

Notes

This vulnerability affects an open-source component, third-party library, protocol, or proprietary implementation that could be used by different products. For more information, please see: https://github.com/abrt/abrt/commit/3c1b60cfa62d39e5fff5a53a5bc53dae189e740e ; BOD 26-04: https://www.cisa.gov/news-events/directives/bod-26-04-prioritizing-security-updates-based-risk ; Forensics Triage Requirements: https://www.cisa.gov/news-events/directives/bod-26-04-implementation-guidance-prioritizing-security-updates-based-risk ; https://nvd.nist.gov/vuln/detail/CVE-2015-5287

External References

Concerned about this vulnerability affecting your clients?

Our team can help you assess exposure and plan remediation.

See Partner Options

Data sourced from the CISA Known Exploited Vulnerabilities catalog. CISA does not endorse any commercial product or service.